MRVI Long Put Strategy

MRVI (Maravai LifeSciences Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology.

MRVI (Maravai LifeSciences Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.57B, a beta of 0.58 versus the broader market, a 52-week range of 2.28-7.44, average daily share volume of 2.7M, a public-listing history dating back to 2020, approximately 416 full-time employees. These structural characteristics shape how MRVI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.58 indicates MRVI has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long put on MRVI?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

MRVI snapshot

As of August 14, 2026, spot at $5.72, ATM IV 110.90%, IV rank 36.21%, expected move 31.79%. The long put on MRVI below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long put structure on MRVI specifically: MRVI IV at 110.90% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 31.79% (roughly $1.82 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MRVI expiries trade a higher absolute premium for lower per-day decay. Position sizing on MRVI should anchor to the underlying notional of $5.72 per share and to the trader's directional view on MRVI stock.

MRVI long put setup

The MRVI long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MRVI at $5.72 on that close, the first option leg uses a $5.72 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MRVI chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MRVI shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$5.72N/A

MRVI long put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

MRVI long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on MRVI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long put on MRVI

Long puts on MRVI hedge an existing long MRVI stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying MRVI exposure being hedged.

MRVI thesis for this long put

The market-implied 1-standard-deviation range for MRVI extends from approximately $3.90 on the downside to $7.54 on the upside. A MRVI long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long MRVI position with one put per 100 shares held. Current MRVI IV rank near 36.21% is mid-range against its 1-year distribution, so the IV signal is neutral; the long put thesis on MRVI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, MRVI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MRVI-specific events.

MRVI long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MRVI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MRVI alongside the broader basket even when MRVI-specific fundamentals are unchanged. Long-premium structures like a long put on MRVI are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current MRVI chain quotes before placing a trade.

Frequently asked questions

What is a long put on MRVI?
A long put on MRVI is the long put strategy applied to MRVI (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With MRVI stock at $5.72 on the most recent close, the strikes shown on this page are snapped to the nearest listed MRVI chain strike and the premiums come straight from that session's bid/ask midpoint.
How are MRVI long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the MRVI long put priced from the end-of-day chain at a 30-day expiry (ATM IV 110.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MRVI long put?
The breakeven for the MRVI long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MRVI market-implied 1-standard-deviation expected move in the same options snapshot is approximately 31.79%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on MRVI?
Long puts on MRVI hedge an existing long MRVI stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying MRVI exposure being hedged.
How does current MRVI implied volatility affect this long put?
MRVI ATM IV is at 110.90% with IV rank near 36.21%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related MRVI analysis